©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2018; 9(9): 141-148
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141
Effects of antidiabetic drugs on epicardial fat
Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Athens 18536, Greece
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Correspondence to: Athanasia Papazafiropoulou, MD, MSc, PhD, Attending Doctor, Research Scientist, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr
Telephone: +30-697-996483
Received: April 20, 2018
Peer-review started: April 21, 2018
First decision: June 8, 2018
Revised: June 19, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: September 15, 2018
Processing time: 147 Days and 8.6 Hours
Peer-review started: April 21, 2018
First decision: June 8, 2018
Revised: June 19, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: September 15, 2018
Processing time: 147 Days and 8.6 Hours
Core Tip
Core tip: In this review, we aim to create a concise overview of the pathophysiology concerning the epicardial fat deposits on a type 2 diabetic individual, while, delving into the intricacies of each antidiabetic drug and exploring the manner by which it interacts with visceral fat accumulation in the sub-pericardial space.